MRD Testing Market

Minimal residual disease (MRD) refers to the small number of cancer cells that remain in the body after treatment. The number of remaining cells may be so small that they do not cause any physical signs or symptoms and often cannot even be detected through traditional methods, such as viewing cells under a microscope and/or by tracking abnormal serum proteins in the blood. An MRD positive test result means that residual (remaining) disease was detected. A negative result means that residual disease was not detected,The most widely used tests to measure MRD are flow cytometry, polymerase chain reaction (PCR) and next-generation sequencing (NGS).

MRD Testing Market contains market size and forecasts of MRD (Minimal Residual Disease) Testing in global, including the following market information:

Global MRD (Minimal Residual Disease) Testing Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global MRD (Minimal Residual Disease) Testing Market Sales, 2017-2022, 2023-2028, (Units)

Global top five MRD (Minimal Residual Disease) Testing companies in 2021 (%)

The global MRD (Minimal Residual Disease) Testing market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Flow Cytometry Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of MRD (Minimal Residual Disease) Testing include ICON plc, ArcherDX(Invitae), ARUP Laboratories, Asuragen, Cergentis B.V., Bio-Rad Laboratories, Mission Bio, Guardant Health and Invivoscribe, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the MRD (Minimal Residual Disease) Testing manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global MRD (Minimal Residual Disease) Testing Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (Units)

Global MRD (Minimal Residual Disease) Testing Market Segment Percentages, by Type, 2021 (%)

Flow Cytometry

Polymerase Chain Reaction (PCR)

Next-Generation Sequencing (NGS)

Global MRD (Minimal Residual Disease) Testing Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (Units)

Global MRD (Minimal Residual Disease) Testing Market Segment Percentages, by Application, 2021 (%)

Specialty Clinics and Hospitals

Diagnostic Laboratories

Research Institutions

Global MRD (Minimal Residual Disease) Testing Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (Units)

Global MRD (Minimal Residual Disease) Testing Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies MRD (Minimal Residual Disease) Testing revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies MRD (Minimal Residual Disease) Testing revenues share in global market, 2021 (%)

Key companies MRD (Minimal Residual Disease) Testing sales in global market, 2017-2022 (Estimated), (Units)

Key companies MRD (Minimal Residual Disease) Testing sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

ICON plc

ArcherDX(Invitae)

ARUP Laboratories

Asuragen

Cergentis B.V.

Bio-Rad Laboratories

Mission Bio

Guardant Health

Invivoscribe

LabCorp

Inivata

Natera

NeoGenomics Laboratories

Opko Health

Quest Diagnostics

Sysmex Corporation

Adaptive Biotechnologies